Ontology highlight
ABSTRACT:
SUBMITTER: Oguejiofor K
PROVIDER: S-EPMC5362415 | biostudies-literature | 2017 Feb
REPOSITORIES: biostudies-literature
Oguejiofor Kenneth K Galletta-Williams Henry H Dovedi Simon J SJ Roberts Darren L DL Stern Peter L PL West Catharine M L CM
Oncotarget 20170201 9
Immunotherapies are beginning to revolutionise treatment paradigms in oncology with monoclonal antibodies (mAb) targeting T-cell co-inhibitory (e.g. PD-1/PD-L1) and co-stimulatory pathways (e.g. CTLA-4/CD28) demonstrating clinical utility. Some clinical studies demonstrate that responsiveness to PD-1/PD-L1 mAb therapy is greater in patients with expression of PD-L1 in the tumour microenvironment. However, robust responses have also been observed in patients with low or absent expression of PD-L1 ...[more]